Mandelia Ashish's most recent trade in Mersana Therapeutics Inc was a trade of 75,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 16,667 | 16,667 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 4,519 | 56,907 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 4,519 | 0 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 4,166 | 12,501 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 4,166 | 61,073 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 0.58 per share. | 15 Jan 2025 | 3,554 | 57,519 (0%) | 0% | 0.6 | 2,061 | Common Stock |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 4,783 | 4,783 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 4,783 | 54,179 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 0.63 per share. | 14 Jan 2025 | 1,791 | 52,388 (0%) | 0% | 0.6 | 1,128 | Common Stock |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 2,646 | 50,403 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 2,646 | 5,292 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 0.66 per share. | 13 Jan 2025 | 1,007 | 49,396 (0%) | 0% | 0.7 | 665 | Common Stock |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 30,000 | 0 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 30,000 | 55,973 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 01 Oct 2024 | 4,855 | 51,118 (0%) | 0% | 2 | 9,710 | Common Stock |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 1.96 per share. | 01 Oct 2024 | 3,361 | 47,757 (0%) | 0% | 2.0 | 6,588 | Common Stock |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2024 | 16,667 | 16,667 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Mandelia Ashish | VP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 2.71 per share. | 13 Jan 2024 | 5,025 | 23,328 (0%) | 0% | 2.7 | 13,618 | Common Stock |
| Mersana Therapeutics Inc | Mandelia Ashish | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 4,783 | 23,001 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 4,783 | 9,566 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Mandelia Ashish | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 4,519 | 27,520 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 4,519 | 4,519 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Mandelia Ashish | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 2,645 | 18,218 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Mandelia Ashish | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 2,645 | 7,938 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Mandelia Ashish | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 833 | 28,353 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Mandelia Ashish | VP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 833 | 0 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2023 | 47,625 | 47,625 | - | - | Stock option (right to buy) | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2023 | 10,583 | 10,583 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,784 | 14,349 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,784 | 11,842 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,519 | 9,038 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 4,519 | 16,361 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Sale of securities on an exchange or to another person at price $ 5.74 per share. | 13 Jan 2023 | 3,575 | 13,619 (0%) | 0% | 5.7 | 20,521 | Common Stock |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 833 | 833 | - | - | Restricted stock unit | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2023 | 833 | 17,194 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 28,700 | 28,700 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 19,133 | 19,133 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 5,353 | 5,353 (0%) | 0% | - | Common Stock | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 4,520 | 13,557 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Sale of securities on an exchange or to another person at price $ 5.92 per share. | 14 Jan 2022 | 1,982 | 3,371 (0%) | 0% | 5.9 | 11,733 | Common Stock |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2022 | 833 | 1,666 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Sale of securities on an exchange or to another person at price $ 13.60 per share. | 01 Jul 2021 | 942 | 0 (0%) | 0% | 13.6 | 12,811 | Common Stock |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 27,115 | 27,115 | - | - | Stock Option (right to buy) | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 18,077 | 18,077 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 834 | 834 (0%) | 0% | - | Common Stock | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 834 | 2,499 | - | - | Restricted Stock Units | |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Sale of securities on an exchange or to another person at price $ 21.28 per share. | 15 Jan 2021 | 545 | 0 (0%) | 0% | 21.3 | 11,598 | Common Stock |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.09 per share. | 15 Jan 2021 | 289 | 545 (0%) | 0% | 21.1 | 6,095 | Common Stock |
| Mersana Therapeutics Inc | Ashish Mandelia | VP, Controller | Sale of securities on an exchange or to another person at price $ 26.76 per share. | 04 Jan 2021 | 247 | 0 (0%) | 0% | 26.8 | 6,610 | Common Stock |